Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
- MSD to Launch Silgard 9 on Feb. 24, but Mass Supply in Japan Unlikely Until 2023
February 5, 2021
- Gilead Mulling Japan Entry into PIII Study for Inhaled Version of Veklury
February 5, 2021
- Kyowa Kirin’s 2020 Sales Rise 4.1% on Growth of 3 Strategic Products
February 5, 2021
- Chugai Closes Book with Double-Digit Earnings Growth on Overseas Sales, Royalties
February 5, 2021
- Takeda’s 9-Month Sales Skid 3.6% on Dips in Rare Diseases, Neuroscience
February 5, 2021
- PI/IIa Study for AnGes’ Hypertension Vaccine Confirms Antibody Production
February 5, 2021
- Otsuka Teams Up with US Firm on Development of Gene Testing Kit for Blood Cancers
February 5, 2021
- Daiichi Sankyo Kicks Off Global PII of ADC Patritumab for EGFR-Mutated NSCLC
February 5, 2021
- Kaken to Copromote Mochida’s Forteo Follow-On from April
February 5, 2021
- Drug Makers Moving to Discontinue Ranitidine/Nizatidine Products over Carcinogen Issue
February 4, 2021
- Daiichi Sankyo Commences PI of ADC DS-6000 in US
February 4, 2021
- Eisai’s April-December Profits Slip on Aggressive Investments
February 4, 2021
- US FDA Accepts NDA for Santen/Ube's Glaucoma Drug
February 4, 2021
- Eisai Neurology Chief Says Partners Continue to Stand Behind Aducanumab
February 4, 2021
- Mitsubishi Tanabe’s April-December Sales Down 2.4% over Price Cuts, Generic Erosion
February 4, 2021
- Mitsubishi Tanabe’s Dyskinesia Med Smashes Goal in Japan PII/III, Eyes Submission in FY2021
February 4, 2021
- Ono Earns Japan, Asia Rights to Ribon’s PARP7 Inhibitor
February 3, 2021
- Internal Probe Finds No Physical Evidence, Testimony in Ex-Sandoz Rep’s Residual Drug Resale Case
February 3, 2021
- Yoshindo Files Nesp Biosimilar in Japan
February 3, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…